IndiaTuberculosis profile
Population  2015 1 311 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 480 (380–590) 36 (29–45)
Mortality (HIV+TB only) 37 (21–57) 2.8 (1.6–4.3)
Incidence  (includes HIV+TB) 2 840 (1 470–4 650) 217 (112–355)
Incidence (HIV+TB only) 113 (58–186) 8.6 (4.4–14)
Incidence (MDR/RR-TB)** 130 (88–180) 9.9 (6.7–14)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 136 (78–193) 860 (112–1 610) 995 (191–1 800)
Males 119 (78–161) 1 730 (1 070–2 380) 1 850 (1 150–2 540)
Total 255 (181–328) 2 590 (1 750–3 420) 2 840 (1 470–4 650)
TB case notifications, 2015  
Total cases notified 1 740 435
Total new and relapse 1 667 136
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 67%
          - % pulmonary 82%
          - % bacteriologically confirmed among pulmonary 64%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 59% (36–110)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.2 (0.11–0.36)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 44 652 4%
          - on antiretroviral therapy 40 925 92%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  79 000
(72 000–87 000)
Estimated % of TB cases with MDR/RR-TB 2.5% (2.1–3.1) 16% (14–18)  
% notified tested for rifampicin resistance 6% 60% 275 321
MDR/RR-TB cases tested for resistance to second-line drugs   8 976
Laboratory-confirmed cases MDR/RR-TB: 28 876, XDR-TB: 3 048
Patients started on treatment **** MDR/RR-TB: 26 966, XDR-TB: 2 130
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 74% 1 609 547
Previously treated cases, excluding relapse, registered in 2014 65% 74 368
HIV-positive TB cases, all types, registered in 2014 76% 44 257
MDR/RR-TB cases started on second-line treatment in 2013 46% 21 093
XDR-TB cases started on second-line treatment in 2013 33% 392
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions) 280
Funding source: 38% domestic, 62% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-10 Data: www.who.int/tb/data